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Mutations in the gene ELOVL4 have been shown to cause stargardt-like macular dystrophy. ELOVL4 is part of a 
family of fatty acid elongases and is yet to have a specific elongase activity assigned to it. We generated Elovl4 
Y270X mutant mice and characterized the homozygous mutant as well as homozygous Elovl4 knockout mice in 
order to better understand the function or role of Elovl4. We found that mice lacking a functional Elovl4 protein 
died perinatally. The cause of death appears to be from dehydration due to faulty permeability barrier formation 
in the skin. Further biochemical analysis revealed a significant reduction in free fatty acids longer than C26 in 
homozygous mutant and knockout mouse skin. These results implicate the importance of these long chain fatty 
acids in skin barrier development. Furthermore, we suggest that Elovl4 is likely involved in the elongation of 
C26 and longer fatty acids. 
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1.  Introduction 
Using a positional cloning approach, ELOVL4 
was identified as the causal disease gene responsible 
for stargardt-like macular dystrophy (STGD3, MIM 
600110), an autosomal dominant form of juvenile 
macular degeneration characterized by decreased 
visual acuity, macular atrophy, and extensive flecks [1, 
2]. The disease-causing gene ELOVL4 encodes a pro-
tein with sequence and structural similarities to the 
ELO family of proteins[3, 4]. The ELO family of pro-
teins is involved in the elongation of long chain fatty 
acids, suggesting that ELOVL4 may have a similar 
function (hence the name, ELOVL), and is highly ex-
pressed in rod and cone photoreceptor cells[4-6]. Se-
quence analysis of human ELOVL4 cDNA predicts a 
protein of 314 amino acids that share homology with 
members of the yeast Elo (elongation of long chain 
fatty acid) family and the human ELO1 homolog 
(HELO1) [4, 7]. HELO1 and the ELO family members 
possess biochemical features that suggest their par-
ticipation in reduction reactions occurring during fatty 
acid elongation [8, 9].   
Mutational analysis of the ELOVL4 gene in five 
large STGD-like macular dystrophy pedigrees re-
vealed a 5 base-pair deletion, resulting in a frame-shift 
and the introduction of a stop codon, 51 codons from 
the end of the coding region [4]. Subsequently, two 
single base-pair deletions, 789delT and 794delT, in 
ELOVL4 were identified in an independent large Utah 
pedigree, confirming the role of the ELOVL4 gene in a 
subset of dominant macular dystrophies [10]. Both the 
5 base-pair deletion and the two single base-pair dele-
tions are predicted to result in a similar truncated 
ELOVL4 protein. A third mutation in ELOVL4, 
270stop, which should also generate a truncated 
ELOVL4 protein, has been identified in a Dutch family 
with dominant STGD [11]. In addition, a recent report 
suggest that variants in ELOVL4 may predispose in-
dividuals to AMD[12].   
The mutant ELOVL4 misfolds and sequesters the 
wild type ELOVL4 into a aggregated form in cell cul-
tures, suggesting a dominant negative mechanism by 
which mutant ELOVL4 causes macular degeneration 
in humans[13-17]. We have further shown lipofuscin 
accumulation, electroretinogram abnormality, and 
RPE and photoreceptor degeneration in mutant 
ELOVL4 transgenic mice[18]. Mice heterozygous for 
the Elovl4 5base-pair deletion developed progressive 
photoreceptor degeneration, while mice haploinsuffi-
cient for Elovl4 developed no noticeable retinal de-
generation [19-21]. This evidence suggests that mutant 
ELOVL4 exerts a dominant negative effect, resulting 
in retinal degeneration. 
Mice lacking a functional copy of Elovl4 die 
perinatally [19, 21, 22]. Mice harboring two 5 base-pair Int. J. Biol. Sci. 2007, 3 
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mutant copies of ELOVL4 have been shown to have 
reduced levels of N-acyl-very long chain fatty acids 
(VLCFAs) and epidermal free fatty acids greater than 
26 carbons in chain length and lack w-0-acylceramide 
and acylglucosylceramide [22]. The alterations in lipid 
content have been suggested to result in a skin per-
meability barrier defect shown to occur in these mice 
and lead to perinatal lethality, but the effect of having 
two mutant copies of Elovl4 cannot be ruled out as a 
possible cause of this lethality.[22].   
We have generated Elovl4 270x mutation knockin 
mice (Elovl4270x/270x) and have found that homozygote 
mice with two mutant copies of Elovl4 die perinatally, 
just like the 5 base-pair mutant and knockout mice 
described previously. We then did a comparative 
study with our Elovl4 knockout (Elovl4-/-) and 
Elovl4270x/270x mice. Both have similar skin phenotypes, 
failing to develop a functional stratum corneum (SC) 
permeability barrier. Skin total lipids of from both 
groups were compared and mice lacking a functional 
copy of ELOVL4 are unable to produce adequate 
quantities of free fatty acids greater than C26. Het-
erozygous animals have lipid levels between the 
wild-type and homozygous mice. Elovl4-/- and 
Elovl4270x/270x mice dehydrate at a rate of about 3% of 
their body weight per hour after birth and die within 
2-3 hours. Lacking a functional copy of Elovl4 leads to 
reduced VLCFA levels affecting the skins ability to 
hold water and ultimately resulting in dehydration 
and death shortly after birth. 
2.  Methods 
Generation and characterization of Elovl4 270x 
knockin mouse 
The targeting vector was derived from a 129/SVJ 
bacterial artificial chromosome clone that includes 
exon 6 from the Elovl4 gene. The construct consisted of 
Y270X mutation and HA tagged Elovl4 fragment, fol-
lowed by a loxP-flanked neomycin resistance (neo) 
cassette, a 5.5-kb 5_ homology arm, and a 3-kb 3_ ho-
mology arm. The herpes simplex virus thymidine 
kinase (TK) was used as a counter selection marker 
(Fig. 1). The targeting vector was electroporated into 
129/SVJ embryonic stem (ES) cells after linearized 
with NotI. Clones in which homologous recombina-
tion resulted in targeted replacement of exon 6 were 
identified by Southern blot analysis of genomic DNA 
digested with EcoRI and BamHI, using external 
probes, and then confirmed by PCR (Fig. 2). A karyo-
typed positive clone was injected and generated chi-
meras, which transmitted the recombinant locus. 
Genotyping of Elovl4 mutant mice was performed by 
PCR on genomic earclips DNA using oligonucleotides 
Elovl4-KI-gt-L(tgtctctctacaccgactgc)/Elovl4-KI-gt-R(tat
tcacgccgtttgatgag) to produce 174-bp and 201-bp 
bands from the wild-type and targeted allele, respec-
tively (Fig. 3). A 280-bp neo cassette fragment was 
amplified from mutant mice using Pgk-neo-Int.F 
(cttgggtggagaggctattc) and Pgk-neo-Int.R (aggtgagat-
gacaggagatc) (Fig. 3). Elovl4 mutant mice were main-
tained in a C57BL/6 background. 
Figure 1 Schematic diagram of the Elovl4 locus and targeting construct. The construct contains 5.5 kb and 3 kb of the 5’ and 
3’ exon6 genomic sequence. A HA tag was inserted before the induced Y270X mutation. A floxed PGKNEO (Neo), positive 
selection marker, was also inserted into exon6. There is a HSV-TK counter selection cassette in the 5’ end of the vector. The 
wild type band expected from EcoRI digestion is 13.9 kb, mutant band is 10.8 kb. The wild type and mutant bands expected 
from BamHI digestion are 7.7 and 5.0 kb, respectively. 
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Figure 2 Southern blot analysis of genomic DNA after di-
gestion with EcoRI, BamHI and hybridization with 5’, 3’ 
external probes. 
 
Figure 3 PCR genotyping of mouse genomic DNA from 
Elovl4
+/+ and Elovl4
+/270x mice. (A) A single 174-bp fragment 
appears in the case of wild-type mice, and a 201-bp fragment 
appears in the case of heterozygous mice along with the 
wild-type fragment. (B) A 280-bp neo cassette fragment 
appears in the case of mutant mice.  
 
Skin permeability assay: 
Embryonic day 19 (E19) mice were dehydrated 
for 1 min each in 25, 50, 75 and 100% methanol/PBS, 
prior to rehydration in PBS. The mice were stained for 
5 min in 0.1% toluidine blue /PBS and then destained 
in a large volume of PBS prior to being photographed 
using a Nikon digital camera. 
Dehydration assay: 
Dehydration was measured by weighing each 
mouse every 30 minutes for 6 hours. The mice are kept 
at 37 degrees C. Water loss is determined by weight 
loss in percent of initial birth weight. Water is pre-
sumed to be the sole contributor to the weight change. 
Littermates are compared to each other and statistical 
analysis is performed using SPSS.   
Tissue preparation: 
E19 embryos are fixed in 4% paraformalde-
hyde/0.1M PBS overnight at 4 degrees C. The embryos 
are then cryoprotected in a graded series of su-
crose/0.1M PBS (10-30%). Embryos are subsequently 
frozen in OCT compound and cryosectioned at 12µm 
in thickness.   
Histological analysis: 
Sectioned slides will be stained with hematoxylin 
and eosin (H&E) and methyl green. H&E sections are 
stained for 3 minutes with hematoxylin followed by 
another 2 minute incubation in eosin and finally de-
hydrated in a series of alcohol rinses. Methyl green 
(0.5%) is used to stain sections for 5 minutes and then 
rinsed. Sections are viewed and photographed with a 
Zeiss Axiovert 200 microscope. 
Mouse tissue lipid extraction: 
Mouse skin is removed from the torso of E19 
mice and frozen on dry ice. Tissues are weighed and 
divided into approximately 0.2g portions. The Folch 
method for total lipid extraction of tissues is used for 
the extraction process. This is followed by a silicic acid 
column separation of lipid classes from Folch washed 
lower phase lipid extracts. Final purification & identi-
fication of lipids from the silicic acid column fractions 
is done by thin layer chromatography on washed sil-
ica gel G plates 0.25u, 20 x 20 cm and capillary GC. 
Two capillary columns differing in polarity are used 
to correctly identify and quantitate the fatty acid 
methyl esters (FAME). The columns that are routinely 
used are: 50 meter x .2u ID x .11u film OV-1 and a 100 
meter x.2u ID x .15u film SP-2560 capillary column. 
Standards of known fatty acid composition and re-
agent blanks are analyzed with each set of samples. 
Individual lipids are expressed as a percentage of the 
total lipid analyzed.   
GC/MS: 
FAME were generated as described above and 
subjected to GC/MS analysis. The sample injection 
volume is 1ul with a 1:35split at injection. Analysis is 
performed on an Agilent 6890/5973 GC/MS operating 
in negative chemical ionization (NCI) mode using 
ammonia as reagent gas (source pressure, 1.6 Torr; 
flow, 2 ml/min). Separation of the fatty acid-PFB es-
ters was accomplished in a 61minute analysis using an 
AT-Silar-100 capillary column (30m x 0.25mm x 0.2 
μm), part # 12632 Alltech Assoc. Inc. Each fatty acid is 
matched to the labeled internal standard of closest 
chain length, retention time, and concentration. Indi-
vidual lipids are expressed as a percentage of the total 
lipid analyzed. 
3.  Results 
Skin permeability 
Toluidine blue normally does not penetrate skin 
with a fully developed stratum corneum [23]. We ex-
amined mice at E19 when the stratum corneum has 
developed. Elovl4270x/270x and Elovl4-/- mice have a thin 
and shiny skin (Figure 4A) while wild type and het-
erozygous mice did not absorb the toluidine blue; 
Elovl4270x/270x and Elovl4-/- mice both absorbed the dye 
and were stained blue accordingly (Figure 4B). Mice 
lacking a functional copy of ELOVL4 are unable to 
develop a proper skin permeability barrier and are 
therefore susceptible to dehydration in a desiccating 
environment and infection. Int. J. Biol. Sci. 2007, 3 
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Figure 4 Permeability barrier failure at E19. (A) 
Elovl4
270x/270x and Elovl4
-/- mice have shiny semi-transparent 
skin compared to wild type pups. (B) Elovl4
270x/270x and 
Elovl4
-/- mice stain blue in a permeability assay demonstrat-
ing their lack of a functional permeability barrier. (C) Av-
erage birth weight for Elovl4
270x/270x and Elovl4
-/- pups (n=10) 
are shone in red and wild type with Elovl4
+/270x and Elovl4
+/- 
(n=33) are in black. Elovl4
270x/270x and Elovl4
-/- pups lose a 
significant amount of water compared to mice with a func-
tional barrier. (one-tailed p-values *< 0.05 **<0.001)  
 
Dehydration  
Because Elovl4270x/270x and Elovl4-/- mice are peri-
natal lethal we removed the pups from pregnant fe-
males at E19. Each pup was weighed after being 
cleaned with a moistened kimmwipe. The pups were 
weighed every 15 minutes for the first hour and then 
every 30 minutes up to 5 hours (Figure 4C). Mice 
lacking a functional copy of Elovl4 lost about 3% of 
their body weights within the first half hour, a signifi-
cant change compared to mice with at least one copy 
of Elovl4. By 5 hours after birth Elovl4270x/270x and 
Elovl4-/- mice lost 15% of their initial body weight 
while wild-type and heterozygous mice lost less than 
2% of their body weight during this period. This loss 
in body weight is attributed to the evaporation of wa-
ter through the skin.   
Skin Histology 
Care was taken to collect sections from the torso 
and face at nearly identical locations in the mice. Im-
ages show the medial dorsal area of the sections from 
the torso (Figure 5A&B) and apical nasal sections 
(Figure 5C). No noticeable skin differences were seen 
in heterozygous animals compared to wild type, but 
mice lacking a functional copy of Elovl4 had several 
changes. Both Elovl4-/- and Elovl4270x/270x mice have 
dermis and epidermis layers that are about 70% of 
normal dermis and epidermis and appear to be com-
pacted (Figure 5A). The outer stratum corneum of the 
epidermis from Elovl4-/- and Elovl4270x/270x is thinner 
and more fragile compared to normal mice (Figure 
5B&C).  
Lipid differences in Elovl4
-/- and Elovl4
270x/270x skin 
We compared skin lipid profiles from Elovl4+/+, 
Elovl4+/-, Elovl4 -/-, Elovl4 +/270x and Elovl4270x/270x mice 
(Tables 1 and 2). Subtle differences were noted in 
omega 3 and omega 6 lipids, but none were significant. 
Significant changes in lipid content were observed in 
VLCFA’s. All 26 carbon fatty acids analyzed, C26:0, 
C26:1, and C26:2, were significantly elevated in mice 
lacking a functional copy of Elovl4 and correspond-
ingly C28:0, C29:0, and C30:0 fatty acids were reduced 
(p<0.01). C30:0 was barely detectable in Elovl4 -/- mice 
and not detected at all in Elovl4270x/270x mice.  
We also examined whether or not these fatty ac-
ids were dependent on Elovl4 expression. Using linear 
regression modeling we found that the 26 carbon fatty 
acids increased while C28:0, C29:0, and C30:0 de-
creased as Elovl4 expression decreased (Figure 6A). 
Without normal expression of Elovl4, C26 fatty acids 
build up and longer fatty acids decrease or almost 
disappear entirely. Taken together with the individual 
statistics, this data suggests that Elovl4 is responsible 
for elongating both saturated and unsaturated 26 car-
bon fatty acids. (Figure 6B)   
4.  Discussion 
We have addressed the functional relevance of 
Elovl4 by utilizing two mouse models, Elovl4-/- and 
Elovl4270x/270x mice. Both models were perinatal lethal 
in the homozygous condition. Elovl4+/- mice develop 
no significant phenotype while Elovl4+/270x have yet to 
be studied by our group, however a 5bp deletion mu-
tant was studied and found to develop a retinal de-
generation-like phenotype with age.[20, 21] By inves-
tigating the perinatal lethality we uncovered a possi-
ble fatty acid elongase activity for Elovl4 and found 
that Elovl4 is necessary for skin barrier development 
and mouse survival. Int. J. Biol. Sci. 2007, 3 
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Figure 5 Histological changes occur in E19 mouse skin. (A)Methyl green stain. (Left) Mice lacking a functional Elovl4 have 
a thin and fragile stratum corneum and have a much thinner epidermis and dermis. (Right) Wild type skin has a well developed, 
thick stratum corneum. Red arrows are drawn across the dermis to show the size difference more clearly. (B) H&E stain. Once 
again mice lacking a functional Elovl4 (left) have a very thin stratum corneum, epidermis and dermis. Hair cells appear to be 
normal. (C) H&E stain showing Elovl4
270x/270x, Elovl4
-/- and wild-type mouse skin. Arrows indicate the SC. 
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Figure 6 Fatty acid alterations suggest Elovl4 may be elongating C26 and C28 fatty acids. (A) Saturated and unsaturated C26 
fatty acids in the skin are greatly increased while longer chain fatty acids are decreased in Elovl4
270x/270x and Elovl4
-/- mice. The 
longest measured C30:0 is almost non-existent. (B) ELOVL4 may function as an elongase for VLCFAs, beginning with C26 
as diagrammed above. 
 
Table 1 Fatty acids measured from E19 skin samples. Significant changes using linear regression on combined Elovl4 270x 
and knockout are in bold. Heterozygous and Homozygous represent combined values of both Elovl4 270x and knockout mice. 
(* decreasing and 
# increasing compared to wild-type) 
 Elovl4+/+ Elovl4+/270x Elovl4270x/270x Elovl4+/- Elovl4-/- Heterozygous  Homozygous 
C8:0 - Octanoic  0.1326%  0.4273%  0.3018%  0.0042%  0.0044%  0.2157%  0.1531% 
C9:0 - Nonanoic  0.7218%  2.4780%  1.9750%  0.0134%  0.0175%  1.2457%  0.9963% 
C10:0 - Capric  0.2219%  0.7687%  0.6058%  0.0033%  0.0044%  0.3860%  0.3051% 
C11:0 - Undecanoic  0.0596%  0.1698%  0.1671%  0.0051%  0.0085%  0.0875%  0.0878% 
C12:0 - Lauric  0.5006%  1.5230%  1.3846%  0.0533%  0.0847%  0.7881%  0.7347% 
C13:0 - Tridecanoic  0.0552%  0.1247%  0.1050%  0.0214%  0.0268%  0.0731%  0.0659% 
C14:0 - Myristic  1.2141%  1.2878%  1.1034%  1.1025%  1.0868%  1.1952%  1.0951% 
C15:0 - Pentadecanoic  0.4841%  0.4167%  0.4651%  0.4655%  0.4073%  0.4411%  0.4362% Int. J. Biol. Sci. 2007, 3 
 
117
C16:0 - Palmitic  19.8759%  17.3620%  14.4374%  22.6083%  21.9211%  19.9851%  18.1792% 
C17:0 - Heptadecanoic  0.4221%  0.3611%  0.3879%  0.4419%  0.4203%  0.4015%  0.4041% 
C18:0 - Stearic  10.9095%  11.9813%  10.3545%  10.3991%  9.1910%  11.1902%  9.7728% 
C20:0 - Arachidic  0.4324%  0.4672%  0.4800%  0.3888%  0.3732%  0.4280%  0.4266% 
C21:0 - Heneicosanoic*  0.0677%  0.0584%  0.0600%  0.0598%  0.0481%  0.0591%  0.0540% 
C22:0 - Behenic  1.3721%  1.1230%  1.2751%  1.3003%  1.1393%  1.2116%  1.2072% 
C23:0 - Tricosanoic  0.4071%  0.2416%  0.3257%  0.4066%  0.3112%  0.3241%  0.3185% 
C24:0 - Lignoceric  6.8596%  4.6244%  7.6147%  7.2884%  6.9943%  5.9564%  7.3045% 
C25:0 - Pentacosanoic  0.9133%  0.4115%  0.7714%  1.2422%  1.1816%  0.8268%  0.9765% 
C26:0 - Hexacosanoic# 3.1668%  1.8104%  4.1685%  4.1543% 4.8060%  2.9823%  4.4873% 
C28:0 - Octacosanoic*  0.1820%  0.0903%  0.0557%  0.1929%  0.0704%  0.1416%  0.0630% 
C29:0 - Nonacosanoic*  0.0180%  0.0106%  0.0086%  0.0194%  0.0055%  0.0150%  0.0070% 
C30:0 - Triacontanoic*  0.0754%  0.0292%  0.0000%  0.0655%  0.0105%  0.0473%  0.0052% 
C10:1 - Caproleic  0.0018%  0.0106%  0.0043% 0.0000%  0.0000% 0.0053%  0.0021% 
C11:1 - Undecaenoic  0.0694%  0.2124%  0.1801%  0.0061%  0.0075%  0.1093%  0.0938% 
C12:1 - Dodecaenoic  0.0059%  0.0080%  0.0129%  0.0013%  0.0028%  0.0046%  0.0078% 
C13:1 - Tridecaenoic  0.0027%  0.0080%  0.0086%  0.0000%  0.0000%  0.0040%  0.0043% 
C15:1 - Pentadecaenoic  0.0084%  0.0292%  0.0214%  0.0010%  0.0019%  0.0151%  0.0116% 
C16:1(n-9) 0.5706%  0.5762%  0.4370%  0.5887%  0.5609%  0.5824%  0.4989% 
C17:1 - Heptadecaenoic  0.5139%  0.1779%  0.2507%  0.2972%  0.7126%  0.2376%  0.4816% 
C18:1(n-9) - Oleic  16.0053% 14.9932%  15.6582%  15.7484%  14.9762% 15.3708%  15.3172% 
C20:1(n-9) - Eicosenoic  0.1894%  0.2230%  0.2400%  0.1567%  0.1667%  0.1898%  0.2034% 
Table 2 Fatty acids measured from E19 skin samples continued. Significant changes using linear regression on combined 
Elovl4 270x and knockout are in bold. Heterozygous and Homozygous represent combined values of both Elovl4 270x and 
knockout mice. (
# increasing compared to wild-type) 
 Elovl4+/+ Elovl4+/270x Elovl4270x/270x Elovl4+/-  Elovl4-/- Heterozygous  Homozygous 
C20:3(n-9) - Mead  0.1953%  0.1671%  0.1071%  0.2297%  0.2196%  0.1984%  0.1634% 
C22:1(n-9) - Erucic  0.1021%  0.1009%  0.1218%  0.1522%  0.1127%  0.1266%  0.1173% 
C24:1(n-9) - Nervonic  1.0265%  1.0195%  1.1293%  1.0112%  0.9972%  1.0153%  1.0632% 
C25:1# 0.0210%  0.0106%  0.0343%  0.0457%  0.0671%  0.0282%  0.0507% 
C26:1 - Hexacosenoic# 0.0835%  0.0584%  0.3708%  0.2243%  0.6395%  0.1414%  0.5051% 
C14:1 - Myristoleic  0.0454%  0.0372%  0.0364% 0.0660%  0.0649% 0.0516%  0.0507% 
C16:1(n-7) - Palmitoleic  3.5607%  2.2245% 2.4490%  4.8816%  4.5576% 3.5531%  3.5033% 
C16:1(n-5) 0.0050%  0.0000%  0.0000%  0.0078%  0.0104%  0.0039%  0.0052% 
C18:1(n-7) - Vaccenic  3.0881%  2.9465%  2.7320%  3.1959%  3.0467%  3.0712%  2.8893% 
C18:1(n-5) 0.0000%  0.0000%  0.0000%  0.0000%  0.0000%  0.0000%  0.0000% 
C20:3(n-7) 0.1179%  0.1195%  0.1328%  0.1050%  0.1024%  0.1123%  0.1176% 
C14:2 - Myristolenic  0.0096%  0.0212%  0.0193%  0.0019%  0.0028%  0.0116%  0.0110% 
C16:2 - Palmitolenic  0.1756%  0.1087%  0.2421%  0.1873%  0.2207%  0.1480%  0.2314% 
C18:2(n-6) - Linoleic  10.1454%  10.6251% 11.9408%  8.9727%  9.2647% 9.7989%  10.6028% 
C18:2(N-6) - Conj - Rumenic  0.1839%  0.3613%  0.3493%  0.0268%  0.0262%  0.1941%  0.1878% 
C18:3(n-6) - Gamma Linolenic  0.1628%  0.1805%  0.1371%  0.1566%  0.1618%  0.1686%  0.1495% 
C20:2(n-6) - Eicosadienoic  3.5252%  0.5044%  0.5250%  6.7875%  7.8270%  3.6460%  4.1760% Int. J. Biol. Sci. 2007, 3 
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C20:3(n-6) - Dihomo-g-linolenic  0.6143%  0.7512%  0.6150%  0.5521%  0.5801%  0.6516%  0.5976% 
C20:4(n-6) - Arachidonic  4.6884%  9.4628%  8.7692%  0.3853%  0.3928%  4.9240%  4.5810% 
C22:2(n-6) - Docosadienoic  0.2134%  0.0717%  0.0686%  0.3878%  0.4528%  0.2297%  0.2607% 
C22:4(n-6) - Adrenic  1.3861%  1.6590%  1.3005%  1.4364%  1.5560%  1.5477%  1.4283% 
C22:5(n-6) - Docosapentaenoic  0.2672%  0.5785%  0.4564%  0.0533%  0.0550%  0.3159%  0.2557% 
C24:2 0.3384%  0.3611%  0.3792%  0.3045%  0.3049%  0.3328%  0.3421% 
C26:2 - Hexacosadienoic# 0.0249%  0.0239%  0.0600% 0.0283%  0.0484% 0.0261%  0.0542% 
C18:3(n-3) - Alpha Linolenic  0.2979%  0.2867%  0.2228%  0.2503%  0.2115%  0.2685%  0.2171% 
C20:3(n-3) 0.0953%  0.1485%  0.0257%  0.0126%  0.0160%  0.0805%  0.0208% 
C20:5(n-3) - Eicosapentaenoic  0.1046%  0.1805%  0.1521%  0.1145%  0.1460%  0.1475%  0.1491% 
C22:3(n-3) - Docosatrienoic  1.2824%  0.0026%  0.0043%  0.0023%  0.0028%  0.0024%  0.0036% 
C22:5(n-3)   0.6352%  0.7829%  0.6792%  0.5535%  0.6417%  0.6682%  0.6604% 
C22:6(n-3) - Docosahexanoic  1.5897%  3.9786%  2.8194%  2.6529%  3.3451%  3.3158%  3.0823% 
 
Mice develop a protective skin barrier during the 
last few days of embryonic development. The most 
crucial layer for this protection is the stratum corneum 
(SC), the uppermost layer of the epidermis. The SC 
filled with ordered stack of cornified envelops (pro-
teins) and lipid bilayers. The lipid bilayers are made 
up of a 1:1:1 ratio of cholesterol, free fatty acids, and 
ceramides. Altering any one of these pools could re-
sult in a faulty barrier. 
Our examinations show that free fatty acids 
longer than C26 are dramatically reduced in Elovl4-/- 
and Elovl4270x/270x mouse skin while the total fatty acid 
pool remains the same. A study of human atopic der-
matitis, a skin disease resulting in impaired perme-
ability barrier function, showed that free fatty acids 
≥C26 are significantly reduced in affected patient’s 
skin.[24] Longer chain fatty acids are more hydropho-
bic and therefore have a greater ability to prevent wa-
ter loss that shorter chain fatty acids. Missing nearly 
entire classes of VLCFAs could disrupt the highly or-
dered state of the SC and allow for water penetration. 
Free VLCFAs are important for ceramide synthe-
sis as well, so missing these fatty acids could affect 
more than one lipid bilayer component of the SC. In 
fact another group has shown that w-0-acylceramides 
are non-existent in mutant Elovl4 mice.[22] Ceramides 
are made up of sphingosine and fatty acids, the former 
requiring free fatty acids itself. Altering the lipid chain 
length of two classes of the “mortar” making up the 
SC could be detrimental to the integrity of the perme-
ability barrier. 
By using both a knockout and a knockin model 
we are able to conclude that it is the lack of the Elovl4 
protein that results in these lipid and skin barrier 
changes and not a gain of function by the mutant pro-
tein. In fact, just missing one functional copy of Elovl4 
is sufficient to significantly reduce lipid levels, though 
not to a detrimental level. Mice with only one copy of 
Elovl4 are able survive normally. Our studies in con-
junction with the previously reported Elovl4 5bp dele-
tion study demonstrate that Elovl4 likely functions in 
elongating C26 to C28 and possibly beyond. Unsatu-
rated and odd chain fatty acids may also use Elovl4 
for similar chain lengths such as C26:1-C28:1 or 
C27-C29. 
The lack of these VLCFAs results in a skin barrier 
defect developing into an atopic dermatitis- like phe-
notype. Dehydration assays show that Elovl4270x/270x 
and Elovl4-/- mice lose about 3% of their initial body 
weight an hour compared to less than 0.3% an hour 
lost by wild type and heterozygous mice. Nearly all of 
the Elovl4270x/270x and Elovl4-/- mice died within 2 hours 
of birth and all died within 4 hours of birth. Altering 
the temperature at which pups were kept did not ap-
pear to affect this rate of water loss. (Data not shown)   
Elovl4 is expressed in other areas of the body. 
The brain in particular has high Elovl4 expression and 
is also a site where loss of a gene would be cause for 
concern. We examined the brain, specifically the hip-
pocampus and cerebellum where Elovl4 expression is 
highest, and found no histological abnormalities. We 
also examined the brain for fatty acid differences in 
Elovl4-/- mice and found no significant changes. Other 
ELO family proteins are expressed in the brain and 
could share redundant function with Elovl4 suggest-
ing a possible reason for the lack of fatty acid changes 
in  Elovl4-/- mice.[22] Histological and a biochemical 
alterations found in the skin seem to be the main cause 
of perinatal lethality in both Elovl4270x/270x and Elovl4-/- 
mice.  
In conclusion, Elovl4 appears to act as a fatty acid 
elongase responsible for the generation of fatty acids 
of chain length greater than C26. This elongase activ-
ity is especially important in the skin, where free fatty 
acids and ceramides are an integral part of the SC, the 
skins permeability barrier. Removing the longest 
VLCFAs results in a smaller, weaker SC that loses its 
ability to prevent water loss in a desiccating environ-
ment.  Elovl4270x/270x and Elovl4-/-  mice consequently 
dehydrate very quickly and die as a result. In an ac-
companying paper [25], Li et al report the depletion of 
certain VLCFA containing ceramides in Elovl4 defi-
cient mice that also have impaired SC barrier function 
and are neonatal lethal. Together these findings dem-
onstrate Elovl4 is essential for lipid biosynthesis, skin Int. J. Biol. Sci. 2007, 3 
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permeability barrier function, and neonatal survival. 
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